ENHANCEMENT OF TUMOR-LIVER CONTRAST-TO-NOISE RATIO WITH GADOBENATE DIMEGLUMINE IN MR-IMAGING OF RATS

被引：21

作者：

KREFT, BP

TANIMOTO, A

STARK, DD

BABA, Y

ZHAO, LH

CHEN, JT

COMPTON, CC

FINN, JP

CAVAGNA, FM

机构：

[1] Departments of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

[2] Departments of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

[3] Department of Radiology, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts

[4] Department of R&D Division, Bracco SpA, Milan

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 01期

关键词：

CONTRAST ENHANCEMENT; GADOLINIUM; LIVER; MR; LIVER NEOPLASMS; RELAXOMETRY;

D O I：

10.1002/jmri.1880030109

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The efficacy for tumor detection of the hepatocyte-specific contrast agent gadobenate dimeglumine (gadolinium-BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histologic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5-10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor-free parenchyma by 15-20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor-free parenchyma and nonspecific tumor enhancement, tumor-liver contrast-to-noise ratios increased 96%-248% in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd-BOPTA/Dimeg. Gd-BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.

引用

页码：41 / 49

页数：9

共 29 条

[1] Stark DD, Wittenberg J, Butch RJ, Et al., Hepatic metast‐ses: randomized, controlled comparison of detection with MR imaging and CT, Radiology, 165, pp. 399-406, (1987)
[2] Heiken JP, Weyman PJ, Lee JKT, Et al., Detection of focal hepatic masses: prospective evaluation with CT. delayed CT. CT during arterial portography, and MR imaging, Radiology, 171, pp. 47-51, (1989)
[3] Chezmar JL, Rumancik WM, Megibow AJ, Et al., Liver and abdominal screening in patients with cancer: CT versus MR imaging, Radiology, 168, pp. 43-47, (1988)
[4] Glazer GM, Aisen AM, Francis IR, Et al., Evaluation of focal hepatic masses: a comparative study of MRI and CT, Gas‐trointest Radiol, 11, pp. 263-268, (1986)
[5] Bousquet JC, Saini S, Stark DD, Et al., Gd‐DOTA: characterization of a new paramagnetic complex, Radiology, 166, pp. 693-698, (1988)
[6] Hamm B, Wolf KJ, Felix R, Conventional and rapid MR imaging of the liver with Gd‐DTPA, Radiology, 164, pp. 313-320, (1987)
[7] Saini S, Stark DD, Brady TJ, Et al., Dynamic spin‐echo MRI of liver cancer using Gd‐DTPA: animal investigation, AJR, 147, pp. 357-362, (1986)
[8] Pavone P, Patrizio G, Buoni C, Et al., Comparison of Gd‐BOPTA with Gd‐DTPA in MR imaging of rat liver, Radiology, 176, pp. 61-64, (1990)
[9] Cavagna F, Tirone P, Felder E, Et al., Hepatobiliary contrast agents for MRI, Liver imaging: current trends and new techniques, pp. 384-393, (1990)
[10] Elizondo G, Fretz CJ, Stark DD, Et al., Preclinical efficacy studies of gadolinium BOPTA as an hepatobiliary contrast agent for MRI (abstr), Book of abstracts: Society of Magnetic Resonance in Medicine 1989, (1989)

← 1 2 3 →